Introduction
The advances in neoadjuvant chemotherapy, modern surgical techniques, and affordable megaprosthesis have increased the number of complex surgeries we undertake in patients with bone tumors in recent times. Infection remains one of the major complications of these surgeries with literature documenting infection rates varying from 2.2% to 19.5%. [1] This is much higher when compared with the 2% infection rates in conventional joint replacement. [2] The higher infection rate in tumor surgeries can be attributed to their complexity, prolonged duration, extensive blood loss, use of megaprosthesis and allografts, and the immunocompromised status of patients receiving cytotoxic chemotherapeutic agents. [3] Surgical site infections (SSIs) often necessitate multiple surgeries and prolonged antibiotic treatment leading to increased morbidity and cost. An appropriate perioperative antibiotic regimen can play a vital role in reducing SSI, but there is little consensus regarding this when it comes to bone tumor surgeries. Current clinical practice is highly varied, with respect to antibiotic type, duration, and mode of administration. [1] The presence of hematoma, edema, and ischemic tissue may reduce the efficacy of intravenous (i.v.) antibiotics by preventing access to the local site. [4] The use of topical antibiotics which enable high concentration at the local site with less systemic toxicity thus offers an attractive avenue to help reduce SSI. [5] Recent studies have shown that topical vancomycin reduces SSI in spinal surgeries. [6, 7] The efficacy of similar topical vancomycin has not yet been studied in bone tumor surgeries. The aim of our study was to evaluate the efficacy of additional topical vancomycin in reducing SSI in bone tumor surgeries.
Materials and Methods
We compared the rates of deep surgical wound infection in two groups of consecutive patients operated for bone tumors of the extremity and pelvis. Information was collected from a prospectively maintained database and patient records. Patients who had evidence of infection at the surgical site or a previous history of infection at the surgical site and those who underwent an amputation were excluded from the study. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
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at the local site with less systemic side effects. There is well-established evidence in general orthopedic literature supporting the local use of antibiotics in the form of antibiotic-coated implants and cement beads. [12] Local powdered vancomycin is inexpensive and has a broad coverage against typical organisms responsible for SSI. There are conflicting reports in literature regarding its efficacy in reducing SSI in spinal surgeries. Sweet demonstrated a 2.6% infection rate in posterior dorso-lumbar spine fusion surgeries done with only i.v cephalexin coverage when compared to 0.2% of infection in dorso-lumbar spine fusion surgeries treated with local vancomycin with i.v. cephalexin. [7] A recent meta-analysis also concluded that the local application of vancomycin in spinal injuries reduces SSI, deep incisional SSI, and Staphylococcus aureus SSI. [6] As against this, a prospective randomized study showed no significant reduction in infection rates with use of local vancomycin in spinal surgeries. [5] Martin too in his study failed to show a significant reduction in infection rate with the use of local vancomycin in spinal deformity correction surgeries. [13] In our study, while the overall infection rate of 7% was comparable to other similar studies. We failed to demonstrate an improvement with the use of additional topical vancomycin (infection rate of 8% in Group A versus 6% in Group B with P = 0.337). [14] [15] [16] This also held true across all the subsets for individual types of surgeries [ Table 2 ]. Although our study is the only study to analyze the effect of additional local vancomycin in SSI in bone tumor surgeries, it does have its limitations. It is a retrospective study which includes mixed etiologies. Our definition of infection included only wounds which required surgical intervention thus possibly missing out on infections which subsided with medical treatment alone. This is unlikely to be a major drawback as deep infection which was our parameter for comparison usually involves reoperation as a standard treatment. [9] We used 1 g of vancomycin powder, which may not be sufficient to prevent infection for these large incisions, and further studies are needed to evaluate whether an increased amount would be more beneficial. [13] The adjutant treatments (chemotherapy and radiotherapy) received between two groups was not significant. Other confounding variables which may contribute to postoperative infections, such as duration of surgery, blood loss, and other medical comorbidities were not evaluated. In spite of these shortcomings, we feel that this study with relatively large numbers provides a springboard for similar prospective studies that aim to rationalize perioperative antibiotic usage in bone tumor surgeries with a view to reduce SSI.
Conclusion
While our data suggest that the addition of topical vancomycin prior to wound closure in patients operated for bone tumors does not decrease the incidence of SSI further investigation of this technique using a case-controlled methodology with an increase in vancomycin dose may be warranted.
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Statistical analysis
All statistical analyses were carried out with the IBM Statistical Package for the Social Sciences (SPSS) version 20, (United states of America). P < 0.05 was considered statistically significant.
Results
A total of 31 patients of the 475 (7%) patients available for analysis developed SSI [ Table 2 ]. Sixteen (52%) of these patients developed an infection within 4 weeks of surgery. A subset analysis of the infection rate based on type of surgery [i.e., endoprosthetic reconstruction, use of internal fixation devices, extracorporeal irradiation and reimplantation, strut allograft is shown in Table 3 ].
Discussion
The rate of SSI following surgery for bone tumor varies from 2.2% to 19.5%. [1] In Hendersons' series, infection was found to be most common cause of failure of megaprosthesis accounting for 34% of cases.
[10] SSI after bone tumor surgery can have disastrous consequences. Jeys et al. series of 1261 patients undergoing endoprosthestic replacement documented the risk of amputation being as high as 19% in patients with proven infection. [11] Local administration of antibiotic at the surgical site before wound closure theoretically achieves high concentration This is an interesting case since testicular metastasis in Wilms' tumor is rare, ipsilateral spread can be caused through spermatic vein, and use or radiation therapy is feasible (with partial response) even after multiple recurrences. [1] [2] [3] It also teaches us that retrograde venous and transcoelomic spread may potentially be prevented by spermatic vein ligation immediately before nephrectomy.
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